Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Hanahan

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Cancer Discovery|January 13, 2022
Hallmarks of Cancer: New DimensionsDouglas Hanahan
Cell|January 30, 2026
Hallmarks of cancer-Then and now, and beyondDouglas Hanahan
Lancet (London, England)|December 20, 2013
Rethinking the war on cancerDouglas Hanahan
Nature Reviews. Cancer|July 25, 2008
Modes of resistance to anti-angiogenic therapyGabriele Bergers, Douglas Hanahan
Cancer Cell|March 14, 2023
Cancer hallmarks intersect with neuroscience in the tumor microenvironmentDouglas Hanahan, Michelle Monje
Cancer Cell|June 28, 2002
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesisTheresa Lopez, Douglas Hanahan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2004
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancerKristian Pietras, Douglas Hanahan
Cell|February 10, 2018
A Subset of Cancer-Associated Fibroblasts Determines Therapy ResistanceJoerg Huelsken, Douglas Hanahan
Cell|April 2, 2013
Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasionLeanne Li, Douglas Hanahan
Cell Cycle (Georgetown, Tex.)|November 13, 2004
Multiple roles for cysteine cathepsins in cancerJohanna A Joyce, Douglas Hanahan
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Cancer Discovery|January 13, 2022
Hallmarks of Cancer: New DimensionsDouglas Hanahan
Cell|January 30, 2026
Hallmarks of cancer-Then and now, and beyondDouglas Hanahan
Lancet (London, England)|December 20, 2013
Rethinking the war on cancerDouglas Hanahan
Nature Reviews. Cancer|July 25, 2008
Modes of resistance to anti-angiogenic therapyGabriele Bergers, Douglas Hanahan
Cancer Cell|March 14, 2023
Cancer hallmarks intersect with neuroscience in the tumor microenvironmentDouglas Hanahan, Michelle Monje
Cancer Cell|June 28, 2002
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesisTheresa Lopez, Douglas Hanahan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2004
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancerKristian Pietras, Douglas Hanahan
Cell|February 10, 2018
A Subset of Cancer-Associated Fibroblasts Determines Therapy ResistanceJoerg Huelsken, Douglas Hanahan
Cell|April 2, 2013
Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasionLeanne Li, Douglas Hanahan
Cell Cycle (Georgetown, Tex.)|November 13, 2004
Multiple roles for cysteine cathepsins in cancerJohanna A Joyce, Douglas Hanahan
Pageof 11